Published in J Addict Med on September 01, 2007
A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction (2008) 2.45
Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis (2011) 2.12
Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. JAMA Intern Med (2014) 1.86
Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend (2008) 1.79
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health (2010) 1.66
Addressing the HIV/AIDS epidemic among Puerto Rican people who inject drugs: the need for a multiregion approach. Am J Public Health (2014) 1.62
Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users. J Psychoactive Drugs (2009) 1.20
Developing and Implementing a New Prison-Based Buprenorphine Treatment Program. J Offender Rehabil (2010) 1.07
A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend (2014) 1.00
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus (2012) 0.97
Buprenorphine-naloxone maintenance following release from jail. Subst Abus (2012) 0.92
Health outcomes and retention in care following release from prison for patients of an urban post-incarceration transitions clinic. J Health Care Poor Underserved (2014) 0.92
Effect of incarceration history on outcomes of primary care office-based buprenorphine/naloxone. J Gen Intern Med (2010) 0.90
Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat (2013) 0.88
Commentary on Larney (2010): a call to action-opioid substitution therapy as a conduit to routine care and primary prevention of HIV transmission among opioid-dependent prisoners. Addiction (2010) 0.85
Improving healthcare for incarcerated women. J Womens Health (Larchmt) (2010) 0.84
Characteristics of inmates witnessing overdose events in prison: implications for prevention in the correctional setting. Harm Reduct J (2009) 0.84
Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status. J Drug Issues (2014) 0.82
Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract (2015) 0.81
Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners. Drug Alcohol Depend (2015) 0.77
Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions. Subst Abuse Rehabil (2016) 0.75
A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. Drug Alcohol Depend (2017) 0.75
"I Kicked the Hard Way. I Got Incarcerated." Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments. J Subst Abuse Treat (2015) 0.75
Recent Incarceration and Buprenorphine Maintenance Treatment Outcomes Among HIV-positive Patients. Subst Abus (2016) 0.75
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction (2008) 2.45
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend (2007) 2.22
A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry (2006) 2.20
A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat (2009) 2.03
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Why don't out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy (2008) 1.73
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin Cancer Res (2012) 1.64
A Study of Methadone Maintenance For Male Prisoners: 3-Month Postrelease Outcomes. Crim Justice Behav (2008) 1.54
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs (2009) 1.42
A novel opioid maintenance program for prisoners: report of post-release outcomes. Am J Drug Alcohol Abuse (2005) 1.35
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res (2010) 1.34
Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol (2012) 1.31
A novel opioid maintenance program for prisoners: preliminary findings. J Subst Abuse Treat (2002) 1.27
Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend (2011) 1.26
Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict (2009) 1.24
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer (2010) 1.24
Alpha-v integrins as therapeutic targets in oncology. Cancer Invest (2007) 1.22
Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users. J Psychoactive Drugs (2009) 1.20
Factors that predict adolescent motivation for substance abuse treatment. J Subst Abuse Treat (2003) 1.13
SBIRT for adolescent drug and alcohol use: current status and future directions. J Subst Abuse Treat (2013) 1.12
Rapid HIV testing for individuals on probation/parole: outcomes of an intervention trial. AIDS Behav (2013) 1.10
Interim methadone treatment: impact on arrests. Drug Alcohol Depend (2009) 1.09
The relationship between services delivered and substance use outcomes in New Mexico's Screening, Brief Intervention, Referral and Treatment (SBIRT) Initiative. Drug Alcohol Depend (2011) 1.09
Gender Differences Among In- and Out-of-Treatment Opioid-Addicted Individuals. Am J Drug Alcohol Abuse (2009) 1.08
Developing and Implementing a New Prison-Based Buprenorphine Treatment Program. J Offender Rehabil (2010) 1.07
The role of patient satisfaction in methadone treatment. Am J Drug Alcohol Abuse (2010) 1.07
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int (2003) 1.06
A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend (2012) 1.05
Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Subst Abus (2012) 1.03
Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res (2004) 1.02
Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoactive Drugs (2014) 1.00
Patterns in admission delays to outpatient methadone treatment in the United States. J Subst Abuse Treat (2011) 0.99
Index of suspicion. Pediatr Rev (2007) 0.99
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res (2010) 0.99
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus (2012) 0.97
Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol (2006) 0.97
Evaluation of a group-based substance abuse treatment program for adolescents. J Subst Abuse Treat (2004) 0.96
Medication-assisted treatment research with criminal justice populations: challenges of implementation. Behav Sci Law (2011) 0.92
Correlates of early substance use and crime among adolescents entering outpatient substance abuse treatment. Am J Drug Alcohol Abuse (2004) 0.92
Cognitive ability as a factor in engagement in drug abuse treatment. Am J Drug Alcohol Abuse (2005) 0.92
Intravenous and intranasal heroin-dependent treatment-seekers: characteristics and treatment outcome. Addiction (2007) 0.92
Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict (2013) 0.92
Redefining retention: recovery from the patient's perspective. J Psychoactive Drugs (2011) 0.91
Impact of interim methadone maintenance on HIV risk behaviors. J Urban Health (2010) 0.91
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Clin Cancer Res (2010) 0.91
Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. J Addict Med (2012) 0.90
Role induction: a method for enhancing early retention in outpatient drug-free treatment. J Consult Clin Psychol (2004) 0.90
Implementing a statewide Screening, Brief Intervention, and Referral to Treatment (SBIRT) service in rural health settings: New Mexico SBIRT. Subst Abus (2012) 0.89
Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes. Am J Drug Alcohol Abuse (2009) 0.89
Endoglin for targeted cancer treatment. Curr Oncol Rep (2014) 0.89
Just call it "treatment". Addict Sci Clin Pract (2012) 0.89
African American patients seeking treatment in the public sector: characteristics of buprenorphine vs. methadone patients. Drug Alcohol Depend (2011) 0.88
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med (2012) 0.87
Predicting retention of adolescents in substance abuse treatment. Addict Behav (2004) 0.86
Validation and performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent primary care patients. Addiction (2014) 0.86
Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment. J Addict Med (2013) 0.86
Death in custody: a historical analysis. J Forensic Sci (2007) 0.86
Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev (2006) 0.84
Employment-based abstinence reinforcement promotes opiate and cocaine abstinence in out-of-treatment injection drug users. J Appl Behav Anal (2014) 0.84
Bedside cardiology skills training for the osteopathic internist using simulation technology. J Am Osteopath Assoc (2003) 0.84
Retention in methadone and buprenorphine treatment among African Americans. J Subst Abuse Treat (2013) 0.84
Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction. Drug Alcohol Depend (2011) 0.83
Stroke training of prehospital providers: an example of simulation-enhanced blended learning and evaluation. Med Teach (2005) 0.83
Screening, brief intervention, and referral to treatment (SBIRT) for substance use in a school-based program: services and outcomes. Am J Addict (2012) 0.83
The relationship of social support to treatment entry and engagement: the Community Assessment Inventory. Subst Abus (2010) 0.83
Probability and predictors of remission from life-time prescription drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Psychiatr Res (2012) 0.82
The CRAFFT cut-points and DSM-5 criteria for alcohol and other drugs: a reevaluation and reexamination. Subst Abus (2014) 0.81
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs (2014) 0.81
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors. Clin Cancer Res (2011) 0.80
Probability and predictors of treatment-seeking for prescription opioid use disorders: a national study. Drug Alcohol Depend (2013) 0.80
Buprenorphine Treatment for Probationers and Parolees. Subst Abus (2014) 0.80
Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol (2013) 0.80
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. J Clin Pharmacol (2014) 0.80
Criminal justice referral and incentives in outpatient substance abuse treatment. J Subst Abuse Treat (2013) 0.80
Gender Differences Among Prisoners With Pre-Incarceration Heroin Dependence Participating in a Randomized Clinical Trial of Buprenorphine Treatment. J Offender Rehabil (2013) 0.79
Impact of role induction on long-term drug treatment outcomes. J Addict Dis (2007) 0.79